CS0159
Phase 3Small molecule
CS0159 is one of 112 small molecule programs targeting Obesity. It is currently in Phase 3.
4
Indications
10
Total Trials
4
Active Trials
111
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
177 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
NNC0487-0111
Novo NordiskPhase 3
Cagrisema
Novo NordiskPhase 3
CS0159
CCascade Pharmaceuticals, Inc
Phase 3
Eloralintide
Eli LillyPhase 3
Belantamab Mafodotin-Blmf
Novo NordiskPhase 3
Efsubaglutide Alfa
SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Actemra
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tics2 trials
Primary Biliary Cholangitis2 trials
Obesity1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CS0159. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- CCascade Pharmaceuticals, Inc